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Summary We quantified and examined the kinetics of DNA interstrand cross links (DNA-ISC) caused by Cis
dichlorodiammine platinum (DDP) using the method of alkaline elution in 58 highly purified human ovarian
tumours growing in primary culture. A large heterogeneity in both the quantity and kinetics of DDP induced
DNA-ISC was observed in cultures derived from neoplasms of different patients and from different lesions of
the same patient. In the majority of cases, DNA-ISC lasted for prolonged time intervals after 1 h drug
exposure, being significantly repaired only 48 or 72 h following drug washout. The persistence of DNA-ISC is
probably due to a prolonged formation of these lesions for up to 24 h as assessed by the change in the repair
kinetics that occurred after preventing new DNA-ISC formation by quenching of monoadducts with thiourea.
The inefficient repair of DDP monoadducts appears therefore to be a possible reason for the permanence of
DNA-ISC.
These studies suggest that the long permanence of DNA-ISC in human ovarian cancer could be the basis for
the high selectivity of DDP for this human malignancy.
Cis dichlorodiammine platinum (DDP) is an antitumour agent
active in several human malignancies (Loehrer & Einhorn,
1984). It is certainly the most effective available drug for the
therapy of testicular (Einhorn & Donohue, 1977) and
ovarian cancer (Neijt et al., 1984; Wiltshaw et al., 1979;
Gruppo Interregionale Cooperativo Oncologico Ginecologia,
1987). Although several types of DNA lesions caused by
DDP in the form of adducts, DNA-protein cross links and
DNA-DNA interstrand (DNA-ISC) and intrastrand-crosslinks
have been characterised in vitro using purified DNA or
cancer cells, the biochemical basis for the selectivity of this
compound for germ cell carcinoma is still unknown. Studies
conducted on cell lines derived from testicular cancer sug-
gested that the long lasting DNA-ISC could be important for
the remarkable activity of DDP against this human tumour
(Bedford et al., 1988). These data suggested that an inefficient
repair of DDP-induced DNA damage could be at the basis
of the selective activity of the drug against testicular cancer
cells.
In order to obtain insight into the mechanisms of selec-
tivity of DDP against ovarian carcinomas we have previously
set up methods to grow purified human ovarian cancer cells
in primary culture and have further demonstrated that they
can be used for pharmacological studies (Balconi et al.,
1988). The rationale behind this work was based on the idea
that primary cultures of tumours derived directly from
patients could represent the in vivo biochemical and
biological properties peculiar to ovarian cells better than
established in vitro cancer cell lines (Balconi et al., 1988), and
assuming that the basis for the selective cytotoxicity of DDP
may rely on the in vivo biological characteristics of ovarian
cancer cells.
The aim of the present study was to evaluate whether
information on the kinetics of DDP-induced DNA-ISC
obtained from ovarian cancer cells growing in primary cul-
ture could provide some insight into the mechanisms of
selectivity of DDP cytotoxicity against human ovarian
cancer.
These studies indicate that although there is a high inter-
and intra-subject heterogeneity of DDP induced DNA-ISC in
most cases the DNA-ISC last for long time intervals before
being repaired.
Materials and methods
Clinicalsamples
Out of 93 human ovarian tumours which were successfully
purified and grown in primary culture, 58 samples were used
for the determination of DDP induced DNA-ISC. The main
clinical characteristics of these cases are summarised in Table
I. Thirty-five primary cultures were excluded from the study
because '4C-thymidine incorporation was regarded as
insufficient (i.e. less than 8.000c.p.m. 10-6cells) to perform
the alkaline elution assay. The cancer cells used for evalua-
tion of DNA-ISC were derived from epithelial serous (68%),
endometrioid (19%), mucinous (2%), mixed (7%), undiffer-
entiated (2%) and clear cells (2%) ovarian cancer.
Cell isolation and culture conditions
All specimens of human ovarian tumours were collected
under aseptic conditions. Solid tumours were enzymatically
dissociated and purified by filtration through a 30 tLm mesh
nylon filter, to yield virtually pure tumour cell cluster (Bal-
coni et al., 1988).
The ascitic fluids were centrifuged and the pellet was
layered on a ficoll gradient and then purified by filtering the
resulting cell suspension through a 30Im mesh nylon filter
and collecting the retained tumour cell cluster from the filter.
The homogeneity of the cell suspension was verified by
morphological analysis and by flow cytometry. In the case of
tumours with a DNA aneuploid, flow cytometric analysis of
DNA content before and after the purification procedure was
used to evaluate the ratio of diploid vs aneuploid. The posi-
tivity to monoclonal antibodies OC-125, MOV-2, MOV-19
was used to assess the homogeneity of human ovarian cancer
cells. The cell prepartion was regarded as adequate for
pharmacological studies when the percentage of normal cells
was less than 3-5%.
Culture medium for cells derived from primary tumours
and metastases was KOV, a modification of MCDB 151
previously described (Balconi et al., 1988), supplemented with
3% FBS.
The cells derived from ascitic fluids were grown in RPMI
1640 supplemented with 10% FBS.
All products for tissue culture were purchased from Gibco
Europe Ltd., UK except MCDB 151 (Sigma Chemical Co.,
St Louis, MO).
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Table I Clinical stage and FIGO grade classification (Young et al., 1985) of different
specimens derived from primary tumours, metastases and ascitic fluids
FIGO grade
Clinical Not
Sample stage Borderline 1 2 3 available Total
Primary tumour I 1 - 2 1 4
II - - - 2 2
III - 3 4 15 22
IV - - - 3 3
Not available 2 2
33
Metastasis II - 1
III 2 3 5
IV - 4 4
10
Ascitic fluid I - 1 - 1
III 6 5 1 12
IV - 1 - 1
Not available - - I - 1
15
Total 3 3 14 37 1 58
Drug treatment
DDP was kindly supplied by Bristol-Meyers, New York, NY.
Fresh drug solution was prepared prior to each experiment in
medium with 3% FBS and incubated for 30min at 37°C
before cell treatment. Cells for cytotoxicity experiments and
culture for alkaline elution assays were treated for 1 h with a
single concentration of DDP (40 .tM). This concentration is
similar to the DDP concentration achieved in plasma of
patients who received DDP at a dose of 100 mgm2 (Ver-
morken et al., 1984). After exposure to DDP, cells were
washed with Phosphate Buffered Saline and incubated with
drug free medium for the duration of the assay.
In some experiments, after DDP treatment, cells were
exposed for 1 h to 0.1 M thiourea (TU) (Merck, Darmstadt,
Germany) at the indicated times.
Cytotoxicity
Growing primary cultures exposed for 1 h to DDP were
recovered in drug-free medium for 72 h. At this time cells
were harvested and stained with 0.2% crystal violet dissolved
in 0.1 M citric acid and the resulting stained suspension of
nuclei was counted by a hemocytometer. At least six control
cultures and six treated cultures were used for the cytotoxi-
city assay. The cytotoxicity was expressed as percentage of
growth inhibition of treated cultures as compared to un-
treated controls.
Alkaline elution
DNA-ISC were detected by the alkaline elution technique
(Kohn et al., 1981). Briefly, cells were labelled for 48 h
with 0.051.Ci ml-I of '4C-thymidine (specific activity
61 fCimmole-', New* England Nuclear). A post labelling
chasing of 16 h in medium without 14C-thymidine was per-
formed before DDP treatment.
At the end of the treatment or after different time intervals
in drug-free medium, cells were subjected to 300 rads
x-irradiation, and deposited on a 0.8 Zm pore size poly-
carbonate filter (Nucleopore Corp., Pleasanton, Ca.) and
lysed with 5 ml of 'Iysis solution' (2% SDS, 0.02M
Na2 EDTA, 0.1 M glycine, pH = 10). Two ml of proteinase K
solution (Merck, Darmstadt, Germany) (O.5 mgml-') dis-
solved in lysis solution were then added to the upper
chamber of a Swinnex filter holder, followed by 50 ml of
0.02M EDTA solution adjusted to pH 12.1 with tetrapro-
pylammonium hydroxide (Fluka, Germany) containing 0.1%
SDS. Three hour fractions (approximately 6 ml) were col-
lected, with fractions and filters processed as described (Kohn
et al., 1981). In some experiments irradiated tritium labelled
cells (L1210, mouse leukaemia cells, labelled with 3H-
thymidine, 0.05liCiml-' for 24h, and irradiated with 300
rads) were added as internal standard. Since the results were
very similar when '4C-DNA retention was plotted either vs
the relative retention of 3H-DNA or vs the time of elution,
we then went on to do other experiments without the addi-
tion of internal standard cells and all data were evaluated as
follows:
ISC ( ) i x 300 rads
where r and ro are the fractions of '4C-DNA remaining on
the filter of treated and control cells calculated on the 4th
fraction (corresponding to the elution at 12 h). Each deter-
mination of DNA-ISC was done using two independent cul-
tures for controls and two independent cultures for treated
samples for each time point. The maximal difference of the
ISC values in the two cultures was of 30%.
The area under the curve (AUC) of DNA-ISC vs time was
determined by trapezoidal integration.
Results
We determined the kinetics of DNA-ISC induced by 1 h
exposure to 40tLM DDP in 58 primary cultures of epithelial
ovarian cancer derived from 47 patients. Figure 1 shows the
profile obtained by plotting the mean values of DNA-ISC
against time determined at 6, 9 and 24 h after DDP treat-
ment. The overall kinetics of DDP-induced DNA-ISC in
cultures derived from primary tumours, metastases and
ascites were similar with an increase of DNA-ISC for up to
9 h followed by a plateau between 9 and 24h. The mean
values appeared higher for metastases than for primary
tumours and ascites, but the difference was not statistically
significant. The levels of DNA-ISC measured in the six cul-
tures derived from patients previously treated with
chemotherapy including DDP appeared lower, but no stati-
stical difference was found, due to their limited number.
Table II reports the quantitative analysis of the data of
DNA-ISC with mean and median values of the peak levels
and AUC of DNA-ISC vs time for up to 24 h. The
variability was large and the differences among the various
groups were not statistically significant.
As previously demonstrated in cancer cell lines the correla-
tion between DNA-ISC and growth inhibition caused by
DDP was significant (Figure 2). In this study the evaluation
was done in few cases. The reason was that the assay for cell
growth of primary cultures, treated or untreated with DDP,
was highly variable (the standard deviations of controls290 G. BALCONI et al.
Table II
Peak (rad eq.) Auc 0-24 h (rad eq.)
Mean ± s.e. median (range) Mean ± s.e. Median (range)
Primary tumours 140± 15 118 (40-399) 2443 + 246 2154 (436-6963)
n = 32
Metastases 178 37 181 (53-352) 3218 655 3220 (1056-6388)
n = 9
Ascites 132 23 156 (21-206) 2305 399 2908 (360-3645)
n = 10
DNA-ISC in ovarian cancer cells derived from primary tumours, metastases and
ascitic fluids. Statistical analysis was performed by one way analysis of variance
(completely randomised design).
Time after DDP washout (hours)
Figure 1 Amount of DNA-ISC determined at 6, 9 and 24 h after
I h treatment with 40jLM DDP in 32 primary tumours (A), in
nine metastases (0), in ten ascites (0) from untreated patients
and in seven samples (five ascites, one metastasis, one primary
tumour) from treated patients (A). Values represent the
mean ± s.e. Statistical analysis was performed by one way
analysis of variance (completely randomised design).
Successful cultures of cancer cells derived from different
neoplastic lesions of the same patient were obtained in few
cases and Figure 3 shows comparisons of the kinetics of
DNA-ISC in these cultures. Except in one case illustrated in
panel b where DNA-ISC were similar in cancer cells derived
from ascites as in those derived from two different meta-
stases, in all other cases marked variations in the levels and
in the kinetics of DNA-ISC were observed in cultures of
tumour cells derived from the different neoplastic lesions of
the same patient.
In some cases when sufficient replicates were available the
kinetics of DNA-ISC were evaluated for up to 72 h after
DDP treatment (Figure 4). A decline but no disappearance of
the DNA-ISC was found starting from 24 h and continuing
further between 48 and 72 h.
The plateau of DNA-ISC observed in many cases between
9 and 24 h could be interpreted either as a slow repair of
DNA-ISC or as a steady state level of DNA-ISC in which
the amount of DNA-ISC formed was similar to the amount
of DNA-ISC repaired in the same time interval. In order to
elucidate this point, experiments were designed, in which
ovarian cancer cells were treated either 8 h or 23 h after DDP
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Figure 2 Correlation between the amount of DNA-ISC ex-
pressed as AUC from 0 to 24 h induced by 40gM DDP (1 h
treatment) and the % of growth inhibition with the same drug
treatment. Y = 27.4216 + 0.01 IX R = 0.65 P < 0.05.
ranged between 10 and 45%), and it would have required
many replicates for a meaningful statistical analysis. It was
therefore impossible to carry it out in all cases tested, due to
a limited amount of cells. Further a colony forming assay
could not be applied for the purpose because our purification
method resulted in the isolation of clusters of ovarian cancer
cells and not of single cells (see Materials and methods).
Finally, since the correlation between DNA-ISC and cyto-
toxicity has been previously reported in many cancer cell
lines (Bedford et al., 1987; Ducore et al., 1982; Pera et al.,
1981; Plooy et al., 1984; Zwelling et al., 1979a), we intended
to direct the focus of the present study on the less known
characterisation of the kinetics of DDP-induced DNA-ISC,
rather than to confirm an already well documented correla-
tion between DNA-ISC and cytotoxicity.
300
200
100*
oA
A
5 6 9 24
e
A 0
..-o -
0 6 9 24
300
200
100
400
300
200
100
0
400
300
200
100
0
b
6 9 ~~~24
B6 9 24
f
o.0
*,O------__
0 6 9 24
Time after DDP washout (hours)
Figure 3 Comparative time course of DNA-ISC index after I h
treatment with 401M DDP evaluated in cancer cells of different
neoplastic lesions derived from the same patient. Data are shown
for cultures established from primary tumours (A ), meta-
stases (O-- ) and ascitic fluids (O---- ). Each individual
panel from a to f represents a specific patient. Particularly in
panel b the cultures of metastases were derived from the omen-
tum (--- ) and from the peritoneum (0-- ); in panel c the
primary tumour cultures were derived from the wall (A )
and from the papillary protrusions of the tumour (A ); in
panel d the cultures of the primary tumours were derived from
the right (A - ) and the left ovary (A ) respectively.
The symbols represent the experimental points. When
experiments have been done in duplicate, both experimental
values are reported.
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Figure 4 72 h-time course of DNA-ISC index of individual
ovarian tumour cell cultures derived from eight different patients.
Cancer cells were exposed to 40ylM DDP for 1 h. Each point is
the mean of two determination on two independent cultures.
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Figure 5 Amount of DNA-ISC in ovarian tumour cells after 1 h
treatment with 40uM DDP (O); panel a shows an experiment in
which cells were treated at 8 h (0) or 23 h (A) after DDP
washout with 0.1 M TU for 1 h. Panel b represents another
experiment in which cells were exposed 8 h (0) after DDP
washout to 0.1 M TU for I h.
exposure with TU 0.1 M for 1 h. TU, at the concentration
used, was reported to block the formation of new DNA-ISC
(Zwelling et al., 1979b; Micetich et al., 1983) making an
evaluation of the repair of DNA-ISC possible. Figure 5
shows two representative experiments clearly demonstrating a
rapid decline of DDP-induced DNA-ISC after TU treatment
whereas without TU much higher levels of DNA-ISC per-
sisted for a longer time interval. These results support the
hypothesis of a prolonged formation of DNA-ISC in the cells
studied occurring from potentially crosslinkable mono-
adducts which were not repaired for at least 24 h after DDP
treatment.
Discussion
Many studies were reported on DNA damage caused by
DDP in numerous cancer cell lines. DDP caused DNA-
protein cross-links (Zwelling et al., 1979a), DNA-intrastrand
and DNA-ISC (Zwelling et al., 1979a; Plooy et al., 1984;
Fichtinger-Schepman et al., 1985a,b; 1987). It is still
debatable which are the most important cytotoxic lesions
caused by DDP.
DNA-ISC are relatively infrequent lesions produced by
DDP. It was estimated that DNA-ISC represent less than
1% of the DNA platinations in vitro (Plooy et al., 1984;
Roberts & Friedlos, 1981; Eastman, 1982). Although DDP-
induced DNA-ISC are present in small amounts as compared
to other DNA lesions they could be important because they
alter profoundly the DNA structure and prevent the separa-
tion of the two strands of DNA needed for DNA replication
and transcription. The importance of these DNA lesions is
supported by a considerable amount of experimental
evidence indicating that a good correlation exists between
DDP-induced DNA-ISC and drug cytotoxicity (Bedford et
al., 1987; Ducore et al., 1982; Zwelling et al., 1979a; Plooy et
al., 1984; Pera et al., 1981). Both with purified DNA and in
whole cells DNA-ISC increase over time following the DNA
binding of DDP-derived active species (Micetich et al., 1983;
D'Incalci et al., 1985; Eastman, 1985). It is reasonable to
expect that in cells the kinetics of DNA-ISC are highly
dependent on DNA repair processes and consequently, that
tumours which are particularly sensitive to DDP do not
repair the DNA lesions efficiently. We found that DDP-
induced DNA-ISC in vitro in highly purified human ovarian
cancer cells were present for a very long time after treatment.
This finding corroborates the previously proposed hypothesis
that the selectivity of DDP for some tumours is due to the
low efficiency of repair of these DNA lesions (Dijt et al.,
1988). Bedford et al. (1988) reported that DDP induced
DNA-ISC lasted much longer in a testicular cancer cell line
particularly sensitive to DDP than in a much less sensitive
bladder cancer cell line. No data were available on primary
cultures of human ovarian or testicular cancer. This is to our
knowledge the first attempt to perform a study of molecular
pharmacology on DDP using primary cultures of a human
target tissue.
A plausible explanation for the protracted presence of
DNA-ISC is that human ovarian cancer cells are deficient in
the specific DNA repair systems. Although DNA repair
enzymes with this function were identified so far only in
bacteria (Sancar & Sancar, 1988) they probably do exist in
eukaryotic cells too. The cells we have investigated might
have been deficient in these enzymatic systems. The
experiments conducted with the addition of TU, however, do
not fully support this view. In fact the repair of DDP-
induced DNA-ISC was very rapid in cells in which the
formation of further DNA-ISC was prevented by TU
quenching of monoadducts. These results suggest that a pos-
sible reason for the permanence of DNA-ISC in these cancer
cells could be the inefficient repair ofpotentially crosslinkable
monoadducts more than of DNA-ISC itself formed after
DDP treatment. At this stage we do not know whether this
phenomenon is due to a limited removal of the DDP
monoadducts or eventually to the low levels of thiols (e.g.
glutathione) which can bind DDP monoadducts (Eastman,
1987) preventing the formation of DNA-ISC. Further studies
are needed to elucidate this point possibly using antibodies
which recognise the main DNA adducts formed by DDP
(Fichtinger-Schepman et al., 1985b; 1987; Sundquist et al.,
1987; Poirier et al., 1982).
We cannot correlate the permanence of DNA-ISC to
clinical response to DDP because most patients received
DDP in combination with other drugs. The response rate to
DDP used as single agent in ovarian cancer patients was
reported to be approximately 50% (Young et al., 1985); in
most of our cultures, instead, a protracted permanence of
DNA-ISC was observed. We do not have an explanation for
this discrepancy, but it may well be that the culture system
used by us caused a selection of cells which were more
sensitive to DDP action.
A very high quantitative and kinetic heterogeneity of
DNA-ISC was observed among the cultures derived from
different patients and also comparing cancer cell cultures
derived from different biopsies or from ascites but all from
the same patient. The heterogeneity of human tumours has
been already put forward as an important obstacle to suc-
cessful therapies (Wolf et al., 1987). Intratumour cell-to-cell
heterogeneity in glutathione content has been recently
reported for human ovarian cancer biopsies (Lee et al.,
1989). The present study provides evidence that in advanced
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ovarian cancer the heterogeneity of DDP-induced DNA
damage is great. Data obtained from studying cancer cells
derived from one biopsy do not necessarily apply to the
entire population of cancer cells of the patient. In view of
this finding it seems unlikely that the evaluation of DNA-ISC
can be regarded as a useful assay to predict the final clinical
outcome of DDP therapy in individual ovarian cancers. The
heterogeneity in amounts and kinetics of DNA-ISC can also
be attributed to several other mechanisms which have been
recently demonstrated in cancer cell lines with a different
degree of sensitivity to DDP (Bedford et al., 1987; Ducore et
al., 1982). A possible explanation could be a nonuniform
DDP uptake (Waud, 1987) or a different repair efficiency of
monoadducts and cross-links or a variable concentration of
thioproteins (Andrews et al., 1987; Lee et al., 1989) which
react with DDP lowering its binding capability to DNA. It
would be important to develop methods which allow the
measurements of biochemical determinants of DDP activity
in individual cells. A better knowledge of the mechanisms is
in fact essential to develop tools to counteract tumour resist-
ance to DDP or to enhance the sensitivity to DDP in ovarian
cancer. Considering that DNA repair processes appear to
play an important role in determining the amount and the
duration of DNA damage caused by DDP, it would be
valuable to investigate the effects of DNA repair inhibitors
given in combination with DDP.
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